

14th Global Gator Meeting
Symposium Day Agenda | June 7, 2024
Bilbao, Spain

8:00 – 9:00 a.m.	Registration/Welcome/Coffee
9:00 – 9:10 a.m.	Welcome from Conference Organizers
9:10 – 9:15 a.m.	Welcome from CTI Host
9:15 – 9:30 a.m.	Welcome and Update from College of Pharmacy Dean
9:30 – 10:45 a.m.	Model-Informed Drug Development Block 1 <ul style="list-style-type: none">• Nieves Velez de Mendizabal, Gilead Sciences• Benjamin Weber, Novo Nordisk• Matthias Fueth, F. Hoffman-La Roche• Valvanera Vozmediano, CTI Life Sciences• Megan Gibbs, AstraZeneca
10:45 – 11:15 a.m.	Coffee Break
11:15 – 12:00 p.m.	Real-World Evidence Block <ul style="list-style-type: none">• Tobias Gerhard, Rutgers University• Serena Guo, UF• Almut Winterstein, UF
12:00 – 12:15 p.m.	Presentation of Global Gator Award
12:15 – 12:30 p.m.	Symposium Group Photo
12:30 – 2:00 p.m.	Lunch
2:00 – 3:15 p.m.	Clinical Research Block <ul style="list-style-type: none">• Carol Motycka, UF• Olaf Rose, Paracelsus Medical University• Ina Richling, St. Johannes Hospital, Dortmund• Midas Mulder, Haaglanden Medical Center
3:15 – 3:45 p.m.	Coffee Break
3:45 – 5:00 p.m.	Model-Informed Drug Development Block II <ul style="list-style-type: none">• Stephan Schaller, esqLABS• Mirjam Trame, Certara• Bernd Meibohm, University of Tennessee• Christopher Long, Hesperos• Andreas Kovar, Sanofi

Model-Informed Drug Development Block I	
Nonlinear Pharmacokinetics, Receptor Occupancy, and Soluble Target Engagement as Tools to Assess In Vivo Antibody Bioactivity	Nieves Velez de Mendizabal, Gilead Sciences
De-novo biomarker discovery to enable dose-exposure-biomarkers models for new targets and biology	Benjamin Weber, Novo Nordisk
From Discovery to Market: Individualized Treatment Regimen in Ophthalmology	Matthias Fueth, F. Hoffman-La Roche
Collaboration Showcase: The Importance of Academia-Industry Partnerships	Valvanera Vozmediano, CTI Life Sciences
Application of AI Across the Drug Development Continuum: Case Studies	Megan Gibbs, AstraZeneca

Real-World Evidence Block	
Revisiting Lactic Acidosis Risk in Metformin Treated Patients with Renal Impairment	Tobias Gerhard, Rutgers University
Equity in Access to Obesity Treatment	Serena Guo, UF
Collateral Damage: Unintended Exposure to Teratogenic Medications During Pregnancy	Almut Winterstein, UF

Clinical Research Block	
Interprofessional Education Simulations: Building Teamwork Through Situational Learning	Carol Motycka, UF
Drug Shortage: Reasons, Impact on Patients and Practitioners and Amelioration Strategies	Olaf Rose, Paracelsus Medical University
Transition Between Care Settings - Practice Standards for Medication Management at Hospital Discharge in Germany	Ina Richling, St. Johannes Hospital, Dortmund
Medication Safety in Patients with Liver Cirrhosis	Midas Mulder, Haaglanden Medical Center

Model-Informed Drug Development Block II	
Integrated QSP-PBPK Modelling for Biologics in Drug Discovery and Development	Stephan Schaller, esqLABS
Integrating PMX and QSP Approaches to Guide Step Up Dosing for a Bispecific Antibody	Mirjam Trame, Certara
Pharmacometric Approaches in Preclinical Drug Development of Novel Anti-Infectives	Bernd Meibohm, University of Tennessee
Pharmacokinetic-Pharmacodynamic Modeling for In Vivo Predictions Utilizing Human-on-a-Chip systems	Christopher Long, Hesperos
Development of an Oral Anti-TNF α Inhibitor - Expect the Unexpected	Andreas Kovar, Sanofi